Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral microbiota signatures associated with viremia and CD4 recovery in treatment-naïve HIV-1-infected patients.
Nannini G, Di Gloria L, Russo E, Sterrantino G, Kiros ST, Coppi M, Niccolai E, Baldi S, Ramazzotti M, Di Pilato V, Lagi F, Bartolucci G, Rossolini GM, Bartoloni A, Amedei A. Nannini G, et al. Among authors: lagi f. Microbes Infect. 2024 Jul-Aug;26(5-6):105339. doi: 10.1016/j.micinf.2024.105339. Epub 2024 Apr 16. Microbes Infect. 2024. PMID: 38636822 Free article.
Leptospirosis acquired by tourists in Venice, Italy.
Lagi F, Corti G, Meli M, Pinto A, Bartoloni A. Lagi F, et al. J Travel Med. 2013 Mar-Apr;20(2):128-30. doi: 10.1111/j.1708-8305.2012.00669.x. Epub 2012 Dec 10. J Travel Med. 2013. PMID: 23464722 Free article.
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.
Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group. Borghetti A, et al. Among authors: lagi f. AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. AIDS. 2017. PMID: 28079545 No abstract available.
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.
Santoro MM, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Antoni AMD, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, Sterrantino G. Santoro MM, et al. Among authors: lagi f. Antivir Ther. 2018;23(3):249-257. doi: 10.3851/IMP3197. Antivir Ther. 2018. PMID: 28935850
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu MV, Giacomelli A, Lagi F, Latini A, Bagella P, De Luca A, Di Giambenedetto S, Madeddu G. Baldin G, et al. Among authors: lagi f. HIV Med. 2019 Feb;20(2):164-168. doi: 10.1111/hiv.12688. Epub 2018 Nov 20. HIV Med. 2019. PMID: 30457197 Free article.
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F, Baldin G, Colafigli M, Capetti A, Madeddu G, Kiros ST, Di Giambenedetto S, Sterrantino G. Lagi F, et al. Int J Antimicrob Agents. 2019 Oct;54(4):487-490. doi: 10.1016/j.ijantimicag.2019.06.003. Epub 2019 Jun 11. Int J Antimicrob Agents. 2019. PMID: 31195121
78 results